AI Article Synopsis
- PI3K is a critical target for cancer therapies due to its role in various cancers, making its inhibition a viable treatment strategy.
- Researchers optimized imidazo [1,2-a] pyrazines, leading to the discovery of compound 14 (ETP-46321), known for its strong activity and favorable pharmacokinetics when taken orally.
- In studies, ETP-46321 effectively reduced AKT(Ser473) phosphorylation in a time-dependent manner, correlating with its presence in tumor tissues and demonstrating significant tumor growth inhibition in a mouse model with a K-Ras mutation.
Article Abstract
Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein, we describe the optimization of imidazo [1,2-a] pyrazines, which allow us to identify compound 14 (ETP-46321), with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing. ETP-46321 PK/PD studies showed time dependent downregulation of AKT(Ser473) phosphorylation, which correlates with compound levels in tumor tissue and demonstrating to be efficacious in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation. Treatment with ETP-46321 resulted in significant tumor growth inhibition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2012.03.090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of novel PI3K inhibitors through a scaffold hopping strategy.
Bioorg Med Chem Lett
November 2017
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain. Electronic address:
A scaffold hopping strategy, including intellectual property availability assessment, was successfully applied for the discovery of novel PI3K inhibitors. Compounds were designed based on the chemical structure of the lead compound ETP-46321, a potent PI3K inhibitor, previously reported by our group. The new generated compounds showed good in vitro potency and selectivity, proved to inhibit potently the phosphorylation of AKT in cells and demonstrated to be orally bioavailable, thus becoming potential back-up candidates for ETP-46321.
View Article and Find Full Text PDFBiological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.
Invest New Drugs
February 2013
Health Research Institut Biocruces, Cruces Hospital, Plaza Cruces s/n, Baracaldo 48903, Spain.
Inhibitors of PI3K signaling are of great therapeutic interest in oncology. The phosphoinositide-3-kinase signaling pathway is activated in a variety of solid and non-solid tumors. We have identified an imidazopyrazine derivative, ETP-46321, as a potent inhibitor of PI3Kα [Formula: see text].
View Article and Find Full Text PDFIdentification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Bioorg Med Chem Lett
May 2012
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Article Synopsis
- PI3K is a critical target for cancer therapies due to its role in various cancers, making its inhibition a viable treatment strategy.
- Researchers optimized imidazo [1,2-a] pyrazines, leading to the discovery of compound 14 (ETP-46321), known for its strong activity and favorable pharmacokinetics when taken orally.
- In studies, ETP-46321 effectively reduced AKT(Ser473) phosphorylation in a time-dependent manner, correlating with its presence in tumor tissues and demonstrating significant tumor growth inhibition in a mouse model with a K-Ras mutation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!